RAC 4.02% $1.79 race oncology ltd

Cardioprotection thread, page-518

  1. 917 Posts.
    lightbulb Created with Sketch. 10390
    I have created this chart to visually represent the universal role Bisantrene plays in cardioprotection against common cardiotoxic chemotherapies. A 1 uM dose of Bisantrene significantly improves HCM viability (p < 0.001). The real value for this opportunity is that while providing cardioprotection, Bisantrene improves cancer cell killing in combination with these chemotherapies. There are already 2 clinical trials where Bisantrene is used in combination with moderately cardiotoxic chemotherapies not listed in the figure below that achieved combined ORR of 46% and 40% with no clinically relevant signs of cardiotoxicity.

    A drug with a universal cardioprotection mechanism combined with a universal cytotoxicity mechanism has not existed until now.

    https://hotcopper.com.au/data/attachments/6175/6175653-af6e9f69133057f8aeb9214b9268a98e.jpg
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.79
Change
-0.075(4.02%)
Mkt cap ! $304.8M
Open High Low Value Volume
$1.86 $1.86 $1.76 $348.2K 192.6K

Buyers (Bids)

No. Vol. Price($)
1 5612 $1.77
 

Sellers (Offers)

Price($) Vol. No.
$1.79 3567 1
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
$1.78
  Change
-0.075 ( 5.38 %)
Open High Low Volume
$1.81 $1.86 $1.76 27553
Last updated 15.55pm 14/06/2024 ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.